血管紧张素转化酶抑制剂加钙离子拮抗剂联合用药治疗模式对于轻、中度原发性高血压的临床疗效观察及其对血尿酸水平的影响

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (3): 317-321.

血管紧张素转化酶抑制剂加钙离子拮抗剂联合用药治疗模式对于轻、中度原发性高血压的临床疗效观察及其对血尿酸水平的影响

伍艳

望城县人民医院药剂科,望城 410200,湖南

收稿日期:2011-02-28 修回日期:2011-03-12 出版日期:2011-03-26 发布日期:2011-05-18
作者简介:伍艳,女,学士,主管药师,研究方向:临床药学、心血管药理学。Tel: 0731-88768973 E-mail: wuyan201196@yahoo.cn

Clinical investigation of ACE inhibitor combined with calcium antagonist on the patients with mild to moderate essential hypertension and it's effect on the serum uric acid level

WU Yan

Pharmacy Department of Wangchen People's Hospital, Wangchen 410200 ,Hunan,China

Received:2011-02-28 Revised:2011-03-12 Online:2011-03-26 Published:2011-05-18

摘要/Abstract

摘要： 目的: 比较卡托普利与氨氯地平联合用药与氨氯地平单独使用对于轻、中度原发性高血压患者的血压的调控及其血尿酸水平的影响。方法: 选取本院门诊轻、中度原发性高血压患者80例进行随机、双盲的临床研究,所有患者经过2周清洗期后随机分为两组,其中联合用药组40例,采用卡托普利 25 mg/次,每天2次,加氨氯地平 5 mg/d 处理;钙拮抗剂组40例,采用氨氯地平 5 mg/d 处理,为期8周。对比观察治疗前后血压变化情况。采用全自动生化分析仪检测治疗前后患者空腹血尿酸的变化情况。结果: 联合用药组治疗4周后,平均坐位舒张压由治疗前的(98±7) mm Hg(1 mm Hg=0.133 kPa)下降至(92±8) mm Hg;治疗8周后,平均坐位舒张压为(86±11) mm Hg,治疗后较治疗前显著降低(P<0.05)。钙拮抗剂组,治疗前平均坐位舒张压为(96±8) mm Hg,治疗4周后,平均坐位舒张压为(95±7) mm Hg,与治疗前比较无统计学差异(P＞0.05);治疗8周后,平均坐位舒张压为(90±8) mm Hg,较治疗前显著降低(P＜0.05)。治疗8周后,两组间平均坐位舒张压下降幅度比较,联合用药组降低更为显著(P＜0.05)。联合治疗与钙拮抗剂都能降低患者的血尿酸水平,联合用药组降低程度明显高于钙拮抗剂组(P<0.05)。结论: 早期联合用药治疗轻、中度高血压患者,能够很好地控制轻、中度高血压,同时能够更好地发挥对重要脏器的保护作用。

关键词: 血管紧张素转化酶抑制剂, 钙离子拮抗剂, 高血压, 临床疗效, 血尿酸

Abstract: AIM: To compare the clinical effect of combination of captopri with amlodipine and monotherapy of amlodipine, and the influence on the serum uric acid level.METHODS: 80 patients with mild to moderate essential hypertension were selected and divided into two groups. 40 patients of the study group were treated with captopri (25 mg/capsule, bid) and amlodipine (5 mg, q.d.) for 8 weeks, 40 patients of the control group were treated with amlodipin (5 mg, q.d.) for 8 weeks. The efficacy of both groups was evaluated by comparing the variance of blood pressure and serum uric acid.RESULTS: The blood pressure of the combined therapy was decreased from (98±7)mm Hg to(92±8) mm Hg after 4 weeks and to (86±11)mm Hg after 8 weeks, the difference is statistically significant (P<0.05). The blood pressure of the monotherapy group was (96±8) mm Hg, which is not statistically significant different from (95±7) mm Hg after 4 weeks. The blood pressure of the monotherapy group was (90±8)mmHg after 8 weeks, which is significantly different from (96±8) mm Hg (P<0.05). The decreased extent of the combined therapy group was significantly different from the monotherapy group. The serum uric acid of the two groups were decreased and the decreased extent of the combined therapy was significant than that of monotherapy group.CONCLUSION: The combined therapy for the mild to moderate essential hypertension is an effective strategy and can protect the organ.

Key words: ACE inhibitor, Calcium antagonist, Hypertension, Effect, Serum uric acid

中图分类号:

R544.1

伍艳. 血管紧张素转化酶抑制剂加钙离子拮抗剂联合用药治疗模式对于轻、中度原发性高血压的临床疗效观察及其对血尿酸水平的影响[J]. 中国临床药理学与治疗学, 2011, 16(3): 317-321.

WU Yan. Clinical investigation of ACE inhibitor combined with calcium antagonist on the patients with mild to moderate essential hypertension and it's effect on the serum uric acid level[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(3): 317-321.

参考文献

[1] 许林勇,张伟,杨天伦,等. 西尼地平胶囊治疗轻中度原发性高血压的有效性和安全性临床研究[J]. 中国临床药理学与治疗学,2010,15(5): 555-560.
[2] Barker DJ, Osmond C, Forsen TJ, et al. Maternal and social origins of hypertension [J]. Hypertension,2007,50(3): 565-571.
[3] Nuyt AM, Alexander BT. Developmental programming and hypertension [J].Curr Opin Nephrol Hypertens,2009,18(2): 144-152.
[4] Matsumura K, Ohtsubo T, Oniki H, et al. Gender-related association of serum uric acid and left ventricular hypertrophy in hypertension [J].Circ J,2006,70(7): 885-888.
[5] Perticone F, Maio R, Ruberto C, et al. Kidney function and risk factors for left ventricular hypertrophy in untreated uncomplicated essential hypertension [J].Am J Kidney Dis,2008,52(1): 74-84.
[6] Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials [J].Am J Med,2009,122(3): 290-300.
[7] Morgan TO, Anderson AL, Maclnnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension [J].Am J Hypertens,2001,14(3): 241-247.
[8] Oparil S, Yarows SA, Patel S. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial [J].Lancet,2007,370(9583): 221-229.
[9] Everett BM, Glynn RJ, Danielson E, et al. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial [J].Clin Ther,2008,30(4): 661-672.
[10] Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men [J].J Am Soc Nephrol,2007,18(1): 287-292.
[11] Borges RL, Hirota AH, Quinto BM, et al. Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy [J].J Clin Hypertens,2009,11(5): 253-259.

[1]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[2]	宁思思, 赵玉红, 颜蕾, 唐敏娜, 张凝之, 张泳巧, 崔兆强. 高血压合并慢性肾脏病患者的降压目标之争议[J]. 中国临床药理学与治疗学, 2023, 28(4): 463-467.
[3]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[4]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[5]	张凝之, 赵玉红, 唐敏娜, 张泳巧, 宁思思, 崔兆强. 时辰药理学在高血压治疗中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 418-422.
[6]	崔素梅, 崔兆强. β受体阻滞剂与高血压治疗[J]. 中国临床药理学与治疗学, 2022, 27(4): 423-427.
[7]	李远方, 崔兆强. 高血压合并高尿酸血症的应对之策[J]. 中国临床药理学与治疗学, 2022, 27(4): 428-432.
[8]	徐建飞, 林利. 高血压药物治疗与非药物治疗研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 433-441.
[9]	蒯铮, 张潇伊, 邹云增. 血管紧张素受体脑啡肽酶抑制剂在老年高血压中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 442-445.
[10]	刘桂剑, 程宽, 朱文青, 葛均波. 高血压的药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 446-449.
[11]	黄伊婷, 沈爱宗. 阿法替尼治疗肺癌的临床疗效与安全性[J]. 中国临床药理学与治疗学, 2021, 26(4): 474-480.
[12]	邢开, 龚金玉, 罗建权. 噻嗪类利尿剂相关不良反应的药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(2): 204-212.
[13]	叶鹏, 谭兴, 冷岳奇, 王杨凯, 王伟忠. 基于交感神经系统的高血压非药物治疗研究现状和进展[J]. 中国临床药理学与治疗学, 2021, 26(12): 1335-1343.
[14]	林荣芳, 郑玮玮, 刘亦伟, 林翠鸿, 王长连, 黄品芳. 克罗恩病患者英夫利西单抗相关基因多态性与血药浓度及疗效关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1000-1006.
[15]	谢祥妹，黄志红，刘小菊，薛冰，蓝保珠. 叶酸片联合阿托伐他汀治疗对H型高血压患者同型半胱氨酸及颈动脉粥样硬化的影响[J]. 中国临床药理学与治疗学, 2020, 25(4): 455-459.